Update on the combination of Novozymes and Chr. Hansen: U.S. antitrust regulation waiting period has expired, supporting the path to completion
March 28 2023 - 6:07AM
Update on the combination of Novozymes and Chr. Hansen: U.S.
antitrust regulation waiting period has expired, supporting the
path to completion
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES,
CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION
WHERE SUCH ACTION WOULD BE UNLAWFUL.
MARCH 28, 2023
On December 12, 2022, Novozymes A/S ("Novozymes") and Chr.
Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and
Chr. Hansen propose to combine and create a leading global
biosolutions partner by way of a statutory merger of the two
companies. Reference is made to Chr. Hansen’s company announcement
no. 13 of December 12, 2022.
Today, the statutory pre-closing suspensory waiting period under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended (the "HSR Act"), with respect to the merger agreement and
merger plan between Novozymes and Chr. Hansen has expired. The
expiration of the HSR waiting period was a condition to completion
of the combination, and today’s outcome of the U.S. antitrust
regulation under the HSR Act supports the path to completion.
The completion of the combination remains subject to the
satisfaction of an additional number of conditions set out in the
merger plan, including approval by the Novozymes and Chr. Hansen
shareholders at the extraordinary general meetings scheduled for
March 30, 2023, and certain additional regulatory approvals.
Completion of the combination is expected to occur in the fourth
quarter of 2023 or the first quarter of 2024. Further details on
the expected timing for the completion of the combination will be
published as relevant.
Transaction websiteFor additional information,
visit www.power-with-biology.com or
https://www.chr-hansen.com/en/investors/proposed-merger/.
About Chr. HansenChr. Hansen is a global,
differentiated bioscience company that develops natural ingredient
solutions for the food, nutritional, pharmaceutical, and
agricultural industries. At Chr. Hansen, we are well positioned to
drive positive change through microbial solutions. We have worked
for over 145 years to enable sustainable agriculture, better food
and healthier living for more people around the world. Our
microbial and fermentation technology platforms, including our
broad and relevant collection of around 40,000 microbial strains,
have game-changing potential. Matching customer needs and global
trends, we continue to unlock the power of good bacteria to respond
to global challenges such as food waste, global health and the
overuse of antibiotics and pesticides. As the world’s most
sustainable food ingredients company, we touch the lives of more
than 1 billion people every day. Driven by our legacy of innovation
and curiosity to pioneer science, our purpose – To grow a better
world. Naturally. – is at the heart of everything we do.
About Novozymes Novozymes is the world leader
in biological solutions. Together with customers, partners, and the
global community, we improve industrial performance while
preserving the planet's resources and helping build better lives.
As the world's largest provider of enzyme and microbial
technologies, our bioinnovation enables higher agricultural yields,
low-temperature washing, energy-efficient production, renewable
fuel, and many other benefits that we rely on today and in the
future. We call it Rethink Tomorrow.
Please see attachment.
Contact information
Novozymes:
Investor RelationsTobias Cornelius Björklund+45
3077 8682tobb@novozymes.com
Press RelationsLina Danstrup+45 3077
0552lind@novozymes.com
Chr. Hansen:
Investor RelationsAnders Mohr Christensen+45
2515 2364dkamc@chr-hansen.com
Press RelationsSanne Seyer-Hansen+45 6038
6207dksash@chr-hansen.com
- 2023_Update on the combination of Novozymes and Chr.
Hansen